These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 20683637)

  • 21. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.
    Ramanathan RK; Egorin MJ; Eiseman JL; Ramalingam S; Friedland D; Agarwala SS; Ivy SP; Potter DM; Chatta G; Zuhowski EG; Stoller RG; Naret C; Guo J; Belani CP
    Clin Cancer Res; 2007 Mar; 13(6):1769-74. PubMed ID: 17363531
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models.
    Burger AM; Fiebig HH; Stinson SF; Sausville EA
    Anticancer Drugs; 2004 Apr; 15(4):377-87. PubMed ID: 15057143
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.
    Richardson PG; Chanan-Khan AA; Alsina M; Albitar M; Berman D; Messina M; Mitsiades CS; Anderson KC
    Br J Haematol; 2010 Aug; 150(4):438-45. PubMed ID: 20618337
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study.
    Weigel BJ; Blaney SM; Reid JM; Safgren SL; Bagatell R; Kersey J; Neglia JP; Ivy SP; Ingle AM; Whitesell L; Gilbertson RJ; Krailo M; Ames M; Adamson PC
    Clin Cancer Res; 2007 Mar; 13(6):1789-93. PubMed ID: 17363534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of cell cycle inhibitor UCN-01 in patients with metastatic melanoma: a California Cancer Consortium trial.
    Li T; Christensen SD; Frankel PH; Margolin KA; Agarwala SS; Luu T; Mack PC; Lara PN; Gandara DR
    Invest New Drugs; 2012 Apr; 30(2):741-8. PubMed ID: 20967484
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer.
    Goetz MP; Toft D; Reid J; Ames M; Stensgard B; Safgren S; Adjei AA; Sloan J; Atherton P; Vasile V; Salazaar S; Adjei A; Croghan G; Erlichman C
    J Clin Oncol; 2005 Feb; 23(6):1078-87. PubMed ID: 15718306
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice monitored by Magnetic Resonance Spectroscopy.
    Rodrigues LM; Chung YL; Al Saffar NM; Sharp SY; Jackson LE; Banerji U; Stubbs M; Leach MO; Griffiths JR; Workman P
    BMC Res Notes; 2012 May; 5():250. PubMed ID: 22621282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retaspimycin hydrochloride (IPI-504): a novel heat shock protein inhibitor as an anticancer agent.
    Hanson BE; Vesole DH
    Expert Opin Investig Drugs; 2009 Sep; 18(9):1375-83. PubMed ID: 19642950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
    Gaspar N; Sharp SY; Pacey S; Jones C; Walton M; Vassal G; Eccles S; Pearson A; Workman P
    Cancer Res; 2009 Mar; 69(5):1966-75. PubMed ID: 19244114
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic effects of radiolabeled 17-allylamino-17-demethoxygeldanamycin on human H460 nonsmall-cell lung carcinoma xenografts in mice.
    Sun J; Liu L; Jiang X; Chen D; Huang Y
    Cancer Biother Radiopharm; 2010 Apr; 25(2):155-64. PubMed ID: 20423228
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
    Erlichman C
    Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer.
    Oh WK; Galsky MD; Stadler WM; Srinivas S; Chu F; Bubley G; Goddard J; Dunbar J; Ross RW
    Urology; 2011 Sep; 78(3):626-30. PubMed ID: 21762967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lectin, Galactoside-Binding Soluble 3 Binding Protein Promotes 17-N-Allylamino-17-demethoxygeldanamycin Resistance through PI3K/Akt Pathway in Lung Cancer Cell Line.
    Woo JK; Jang JE; Kang JH; Seong JK; Yoon YS; Kim HC; Lee SJ; Oh SH
    Mol Cancer Ther; 2017 Jul; 16(7):1355-1365. PubMed ID: 28336809
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The HSP90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model.
    Xu Y; Zhu Q; Chen D; Shen Z; Wang W; Ning G; Zhu Y
    Tumour Biol; 2015 Jul; 36(7):5103-8. PubMed ID: 25682284
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG.
    Wang S; Wang X; Du Z; Liu Y; Huang D; Zheng K; Liu K; Zhang Y; Zhong X; Wang Y
    Biochem Biophys Res Commun; 2014 Jul; 450(1):73-80. PubMed ID: 24879994
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.
    Hamid O; Ilaria R; Garbe C; Wolter P; Maio M; Hutson TE; Arance A; Lorigan P; Lee J; Hauschild A; Mohr P; Hahka-Kemppinen M; Kaiser C; Turner PK; Conti I; Grob JJ
    Cancer; 2014 Jul; 120(13):2016-24. PubMed ID: 24676877
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models.
    Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma.
    Francis LK; Alsayed Y; Leleu X; Jia X; Singha UK; Anderson J; Timm M; Ngo H; Lu G; Huston A; Ehrlich LA; Dimmock E; Lentzsch S; Hideshima T; Roodman GD; Anderson KC; Ghobrial IM
    Clin Cancer Res; 2006 Nov; 12(22):6826-35. PubMed ID: 17121904
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).
    Waza M; Adachi H; Katsuno M; Minamiyama M; Tanaka F; Sobue G
    Ann N Y Acad Sci; 2006 Nov; 1086():21-34. PubMed ID: 17185503
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models.
    Banerji U; Sain N; Sharp SY; Valenti M; Asad Y; Ruddle R; Raynaud F; Walton M; Eccles SA; Judson I; Jackman AL; Workman P
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):769-78. PubMed ID: 18193424
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.